Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Corrigendum to "Evaluation of TSPO PET imaging, a marker of glial activation, to study the neuroimmune footprints of morphine exposure and withdrawal" [Drug Alcohol Depend. 170 (2017) 43-50].

Auvity S, Goutal S, Thézé B, Chaves C, Hosten B, Kuhnast B, Saba W, Boisgard R, Buvat I, Cisternino S, Tournier N.

Drug Alcohol Depend. 2019 Jun 5. pii: S0376-8716(19)30162-0. doi: 10.1016/j.drugalcdep.2019.05.002. [Epub ahead of print] No abstract available.

PMID:
31176599
2.

Longitudinal characterization of cognitive and motor deficits in an excitotoxic lesion model of striatal dysfunction in non-human primates.

Lavisse S, Williams S, Lecourtois S, van Camp N, Guillermier M, Gipchtein P, Jan C, Goutal S, Eymin L, Valette J, Delzescaux T, Perrier AL, Hantraye P, Aron Badin R.

Neurobiol Dis. 2019 May 24;130:104484. doi: 10.1016/j.nbd.2019.104484. [Epub ahead of print]

PMID:
31132407
3.

Physical blood-brain barrier disruption induced by focused ultrasound does not overcome the transporter-mediated efflux of erlotinib.

Goutal S, Gerstenmayer M, Auvity S, Caillé F, Mériaux S, Buvat I, Larrat B, Tournier N.

J Control Release. 2018 Dec 28;292:210-220. doi: 10.1016/j.jconrel.2018.11.009. Epub 2018 Nov 8.

PMID:
30415015
4.

Impact of rifampicin-inhibitable transport on the liver distribution and tissue kinetics of erlotinib assessed with PET imaging in rats.

Amor D, Goutal S, Marie S, Caillé F, Bauer M, Langer O, Auvity S, Tournier N.

EJNMMI Res. 2018 Aug 16;8(1):81. doi: 10.1186/s13550-018-0434-0.

5.

Positron Emission Tomography Imaging Reveals an Importance of Saturable Liver Uptake Transport for the Pharmacokinetics of Metoclopramide.

Caillé F, Goutal S, Marie S, Auvity S, Cisternino S, Kuhnast B, Pottier G, Tournier N.

Contrast Media Mol Imaging. 2018 May 8;2018:7310146. doi: 10.1155/2018/7310146. eCollection 2018.

6.

P-Glycoprotein (ABCB1) Inhibits the Influx and Increases the Efflux of 11C-Metoclopramide Across the Blood-Brain Barrier: A PET Study on Nonhuman Primates.

Auvity S, Caillé F, Marie S, Wimberley C, Bauer M, Langer O, Buvat I, Goutal S, Tournier N.

J Nucl Med. 2018 Oct;59(10):1609-1615. doi: 10.2967/jnumed.118.210104. Epub 2018 May 10.

PMID:
29748235
7.

Intravenous infusion for the controlled exposure to the dual ABCB1 and ABCG2 inhibitor elacridar in nonhuman primates.

Goutal S, Langer O, Auvity S, Andrieux K, Coulon C, Caillé F, Gervais P, Cisternino S, Declèves X, Tournier N.

Drug Deliv Transl Res. 2018 Jun;8(3):536-542. doi: 10.1007/s13346-017-0472-6.

PMID:
29294257
8.

Imaging the neuroimmune response to alcohol exposure in adolescent baboons: a TSPO PET study using 18 F-DPA-714.

Saba W, Goutal S, Auvity S, Kuhnast B, Coulon C, Kouyoumdjian V, Buvat I, Leroy C, Tournier N.

Addict Biol. 2018 Sep;23(5):1000-1009. doi: 10.1111/adb.12548. Epub 2017 Sep 25.

PMID:
28944558
9.

Evaluation of TSPO PET imaging, a marker of glial activation, to study the neuroimmune footprints of morphine exposure and withdrawal.

Auvity S, Goutal S, Thézé B, Chaves C, Hosten B, Kuhnast B, Saba W, Boisgard R, Buvat I, Cisternino S, Tournier N.

Drug Alcohol Depend. 2017 Jan 1;170:43-50. doi: 10.1016/j.drugalcdep.2016.10.037. Epub 2016 Nov 8. Erratum in: Drug Alcohol Depend. 2019 Jun 5;:.

PMID:
27875800
10.

Acute Morphine Exposure Increases the Brain Distribution of [18F]DPA-714, a PET Biomarker of Glial Activation in Nonhuman Primates.

Auvity S, Saba W, Goutal S, Leroy C, Buvat I, Cayla J, Caillé F, Bottlaender M, Cisternino S, Tournier N.

Int J Neuropsychopharmacol. 2017 Jan 1;20(1):67-71. doi: 10.1093/ijnp/pyw077.

11.

Strategies to Inhibit ABCB1- and ABCG2-Mediated Efflux Transport of Erlotinib at the Blood-Brain Barrier: A PET Study on Nonhuman Primates.

Tournier N, Goutal S, Auvity S, Traxl A, Mairinger S, Wanek T, Helal OB, Buvat I, Soussan M, Caillé F, Langer O.

J Nucl Med. 2017 Jan;58(1):117-122. doi: 10.2967/jnumed.116.178665. Epub 2016 Aug 4.

12.

Diphenhydramine as a selective probe to study H+-antiporter function at the blood-brain barrier: Application to [11C]diphenhydramine positron emission tomography imaging.

Auvity S, Chapy H, Goutal S, Caillé F, Hosten B, Smirnova M, Declèves X, Tournier N, Cisternino S.

J Cereb Blood Flow Metab. 2017 Jun;37(6):2185-2195. doi: 10.1177/0271678X16662042. Epub 2016 Jan 1.

13.

Imaging the impact of cyclosporin A and dipyridamole on P-glycoprotein (ABCB1) function at the blood-brain barrier: A [(11)C]-N-desmethyl-loperamide PET study in nonhuman primates.

Damont A, Goutal S, Auvity S, Valette H, Kuhnast B, Saba W, Tournier N.

Eur J Pharm Sci. 2016 Aug 25;91:98-104. doi: 10.1016/j.ejps.2016.06.005. Epub 2016 Jun 7.

PMID:
27283486
14.

Validation of a simple HPLC-UV method for rifampicin determination in plasma: Application to the study of rifampicin arteriovenous concentration gradient.

Goutal S, Auvity S, Legrand T, Hauquier F, Cisternino S, Chapy H, Saba W, Tournier N.

J Pharm Biomed Anal. 2016 May 10;123:173-8. doi: 10.1016/j.jpba.2016.02.013. Epub 2016 Feb 15.

PMID:
26907700
15.

Imaging the Impact of the P-Glycoprotein (ABCB1) Function on the Brain Kinetics of Metoclopramide.

Pottier G, Marie S, Goutal S, Auvity S, Peyronneau MA, Stute S, Boisgard R, Dollé F, Buvat I, Caillé F, Tournier N.

J Nucl Med. 2016 Feb;57(2):309-14. doi: 10.2967/jnumed.115.164350. Epub 2015 Nov 19.

16.

Differential influence of propofol and isoflurane anesthesia in a non-human primate on the brain kinetics and binding of [(18)F]DPA-714, a positron emission tomography imaging marker of glial activation.

Saba W, Goutal S, Kuhnast B, Dollé F, Auvity S, Fontyn Y, Cayla J, Peyronneau MA, Valette H, Tournier N.

Eur J Neurosci. 2015 Jul;42(1):1738-45. doi: 10.1111/ejn.12946. Epub 2015 Jun 22.

PMID:
25962575
17.

Influence of P-Glycoprotein Inhibition or Deficiency at the Blood-Brain Barrier on (18)F-2-Fluoro-2-Deoxy-D-glucose ( (18)F-FDG) Brain Kinetics.

Tournier N, Saba W, Goutal S, Gervais P, Valette H, Scherrmann JM, Bottlaender M, Cisternino S.

AAPS J. 2015 May;17(3):652-9. doi: 10.1208/s12248-015-9739-3. Epub 2015 Feb 26.

18.

[18F]DPA-714 PET imaging of translocator protein TSPO (18 kDa) in the normal and excitotoxically-lesioned nonhuman primate brain.

Lavisse S, Inoue K, Jan C, Peyronneau MA, Petit F, Goutal S, Dauguet J, Guillermier M, Dollé F, Rbah-Vidal L, Van Camp N, Aron-Badin R, Remy P, Hantraye P.

Eur J Nucl Med Mol Imaging. 2015 Mar;42(3):478-94. doi: 10.1007/s00259-014-2962-9. Epub 2014 Dec 9.

PMID:
25488184
19.

[¹¹C]befloxatone brain kinetics is not influenced by Bcrp function at the blood-brain barrier: a PET study using Bcrp TGEM knockout rats.

Hosten B, Boisgard R, Jacob A, Goutal S, Saubaméa B, Dollé F, Scherrmann JM, Cisternino S, Tournier N.

Eur J Pharm Sci. 2013 Nov 20;50(3-4):520-5. doi: 10.1016/j.ejps.2013.08.015. Epub 2013 Aug 24.

PMID:
23981334
20.

Effects of selected OATP and/or ABC transporter inhibitors on the brain and whole-body distribution of glyburide.

Tournier N, Saba W, Cisternino S, Peyronneau MA, Damont A, Goutal S, Dubois A, Dollé F, Scherrmann JM, Valette H, Kuhnast B, Bottlaender M.

AAPS J. 2013 Oct;15(4):1082-90. doi: 10.1208/s12248-013-9514-2. Epub 2013 Aug 2.

21.

[(18)F]Fallypride: metabolism studies and quantification of the radiotracer and its radiometabolites in plasma using a simple and rapid solid-phase extraction method.

Peyronneau MA, Saba W, Goutal S, Kuhnast B, Dollé F, Bottlaender M, Valette H.

Nucl Med Biol. 2013 Oct;40(7):887-95. doi: 10.1016/j.nucmedbio.2013.06.003. Epub 2013 Jul 25.

PMID:
23891202
22.

Metabolism and quantification of [(18)F]DPA-714, a new TSPO positron emission tomography radioligand.

Peyronneau MA, Saba W, Goutal S, Damont A, Dollé F, Kassiou M, Bottlaender M, Valette H.

Drug Metab Dispos. 2013 Jan;41(1):122-31. doi: 10.1124/dmd.112.046342. Epub 2012 Oct 12.

PMID:
23065531
23.

Discrepancies in the P-glycoprotein-mediated transport of (18)F-MPPF: a pharmacokinetic study in mice and non-human primates.

Tournier N, Cisternino S, Peyronneau MA, Goutal S, Dolle F, Scherrmann JM, Bottlaender M, Saba W, Valette H.

Pharm Res. 2012 Sep;29(9):2468-76. doi: 10.1007/s11095-012-0776-7. Epub 2012 May 30.

PMID:
22644589
24.

Difficulties in dopamine transporter radioligand PET analysis: the example of LBT-999 using [18F] and [11C] labelling: part II: Metabolism studies.

Peyronneau MA, Saba W, Dollé F, Goutal S, Coulon C, Bottlaender M, Valette H.

Nucl Med Biol. 2012 Apr;39(3):347-59. doi: 10.1016/j.nucmedbio.2011.09.006. Epub 2011 Dec 11.

PMID:
22154687
25.

[18F]DPA-714, [18F]PBR111 and [18F]FEDAA1106-selective radioligands for imaging TSPO 18 kDa with PET: automated radiosynthesis on a TRACERLAb FX-FN synthesizer and quality controls.

Kuhnast B, Damont A, Hinnen F, Catarina T, Demphel S, Le Helleix S, Coulon C, Goutal S, Gervais P, Dollé F.

Appl Radiat Isot. 2012 Mar;70(3):489-97. doi: 10.1016/j.apradiso.2011.10.015. Epub 2011 Nov 11.

PMID:
22104496
26.

Difficulties in dopamine transporter radioligand PET analysis: the example of LBT-999 using [18F] and [11C] labelling Part I: PET studies.

Saba W, Peyronneau MA, Dollé F, Goutal S, Bottlaender M, Valette H.

Nucl Med Biol. 2012 Feb;39(2):227-33. doi: 10.1016/j.nucmedbio.2011.08.003. Epub 2011 Oct 26.

PMID:
22033025
27.

Transport of selected PET radiotracers by human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2): an in vitro screening.

Tournier N, Valette H, Peyronneau MA, Saba W, Goutal S, Kuhnast B, Dollé F, Scherrmann JM, Cisternino S, Bottlaender M.

J Nucl Med. 2011 Mar;52(3):415-23. doi: 10.2967/jnumed.110.079608. Epub 2011 Feb 14.

28.

Staudinger reaction at in-bridgehead positions of phosphorus macrobicyclic compounds.

Bauer I, Gruner M, Goutal S, Habicher WD.

Chemistry. 2004 Aug 20;10(16):4011-6.

PMID:
15317057

Supplemental Content

Loading ...
Support Center